Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TOP1 | P11387 | 3/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742438 | 0.89 | CYP11B1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL6745173 | 0.89 | CYP11B1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL31357665 | 0.84 | CES2 (0.32) | — | |
| SCHEMBL2477020 | 0.82 | PDE2A (0.44) | — | |
| SCHEMBL31287536 | 0.79 | PDE2A (0.45) | PPARGTOP1PDE5ACYP11B1CYP11B2 | |
| SCHEMBL31287512 | 0.77 | TOP1 (0.48) | PPARGTOP1PPARA | |
| SCHEMBL9646398 | 0.77 | PPARG (0.47) | PPARGPPARACSNK1E | |
| SCHEMBL4819936 | 0.77 | CES2 (0.44) | TOP1CYP11B1CYP11B2 | |
| SCHEMBL8499483 | 0.77 | PPARG (0.47) | PPARGPPARACSNK1E | |
| SCHEMBL6152931 | 0.77 | PPARG (0.47) | PPARGPPARACSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373317-B1 | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| US-8741910-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741910-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | disclosed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | disclosed |
| WO-2010065275-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE2A, GUCY1A2, PDE3A | PPARG 641/4885CA2 1875/4885TOP1 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.